peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
We well as boost energy levels, improve symptoms of depression, anxiety, and mental clarity/ cognitive function
Your healthcare team can assess whether your current regimen remains appropriate or requires modification
Funding This work was supported by funding from the Natural Science Foundation of Hunan Province (No
EXCELLENT PRICE-PERFORMANCE RATE: Highly dosed
Samples were electrophoresed (80 V, 0.5 h, then 120 V, 1H) and transferred to polyvinylidene fluoride membranes (280 mA, 1 kda/min)
